$9.000
-0.010 (-0.11%)收盘时
XLO 资讯
XLO 事件
Xilio Therapeutics Appoints Ben Harshbarger as Chief Legal Officer
Xilio Therapeutics announced the appointment of Ben Harshbarger as chief legal officer. recently, he served as chief legal officer at Astria Therapeutics, Inc. until its acquisition.
Xilio Therapeutics Files $250M Mixed Securities Shelf
Xilio Therapeutics files $250M mixed securities shelf
Xilio Therapeutics Announces New Data for XTX601
Xilio Therapeutics announced new preclinical data for XTX601, a masked T cell engager targeting claudin 18.2, at the American Association for Cancer Research Annual Meeting, taking place from April 17-22 in San Diego, California. "The data to be presented at AACR underscore the significant potential of our clinically-validated masking technology to address the central challenge that has limited the advancement of T cell engagers in solid tumors - namely, the inability to achieve meaningful anti-tumor activity without inducing severe systemic toxicities," said Uli Bialucha, Chief Scientific Officer of Xilio Therapeutics. "XTX601 has demonstrated a promising preclinical profile, including potent tumor cell killing across multiple CLDN18.2-expressing tumor models and a favorable tolerability profile in non-human primates, supporting its potential to achieve a wide therapeutic index. Importantly, our modular architecture for masked T cell engagers provides flexibility to rapidly evaluate multiple designs in parallel, including masking of the CLDN18.2 binding domain and/or the addition of a co-stimulatory domain, which enables us to seek to optimize the molecule for the best possible clinical profile."
Xilio Therapeutics Appoints Cheryl Blanchard to Board of Directors
Xilio Therapeutics announced the appointment of Cheryl Blanchard, Ph.D. to the company's board of directors. The company also announced that Christina Rossi has stepped down from its board of directors, effective April 15, 2026.
Xilio Therapeutics Grants 50,050 Stock Options to New Employees
Xilio Therapeutics announced that, effective March 1, 2026, the company granted non-qualified stock options to purchase 50,050 shares of its common stock to two new employees under Xilio Therapeutics' 2022 Inducement Stock Incentive Plan. The stock options have an exercise price of $0.5283 per share, which is equal to the closing price of the company's common stock on February 27, 2026. Each stock option has a ten-year term and will vest as to 25% of the shares underlying the stock option on the first anniversary following commencement of employment, and the remaining 75% of the shares underlying the stock option will vest in 36 equal monthly installments thereafter, subject to continued service with the company or any of its subsidiaries through each applicable vesting date. The stock options are subject to the terms and conditions of Xilio Therapeutics' 2022 Inducement Stock Incentive Plan, as well as the terms and conditions of the stock option agreement covering the grant and were made as an inducement material to the individual entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。